Adial Pharmaceuticals, Inc. (ADIL) Stock Ticker
ADIL right now
Market factors today
Unlock the full ADIL picture
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
ADIL stock facts
| Ticker symbol | ADIL |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $4.0M |
| CEO | Cary John Claiborne |
| Employees | 5 |
| Headquarters | Glen Allen, VA, US |
| IPO date | 2018-07-27 |
| Website | www.adial.com |
What you can see for ADIL on Tickr
Live ADIL price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ADIL report.
Rankings
FAQ
What is the ticker symbol for Adial Pharmaceuticals, Inc.?
The ticker symbol for Adial Pharmaceuticals, Inc. is ADIL, listed on the NASDAQ Capital Market.
What is ADIL?
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for…